Medincell has announced a collaboration with AbbVie to co-develop and commercialise up to six long-acting injectable therapies across multiple therapeutic areas and indications.
Medincell will use its commercial-stage injectable technology platform to formulate such therapies. The company will conduct formulation activities and preclinical studies, including supportive CMC work to advance candidates into clinical trials.
AbbVie will finance and conduct the clinical development for each programme, and will be responsible for regulatory approval, manufacturing and commercialisation.
Christophe Douat, Medincell’s CEO said: “Medincell has entered a new period of growth following the FDA approval of the first product using our technology in April 2023. The full potential of long-acting injectable therapies is getting increasingly recognised.”
Under the terms of the co-development and licensing agreement covering up to 6 initiatives, Medincell will receive a USD $35m upfront payment and is eligible to receive up to $1.9bn in development and commercial milestones ($315 million for each programme).
Medincell is also eligible to receive mid-single to low-double-digit royalties on net sales.
